<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04149535</url>
  </required_header>
  <id_info>
    <org_study_id>92365019</org_study_id>
    <nct_id>NCT04149535</nct_id>
  </id_info>
  <brief_title>PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement</brief_title>
  <acronym>PROTECTED TAVR</acronym>
  <official_title>PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that use of the Sentinel® Cerebral Protection System significantly reduces the
      risk of peri-procedural stroke (≤72 hours) after transcatheter aortic valve replacement
      (TAVR).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of stroke through 72 hours post TAVR procedure or discharge (whichever comes first)</measure>
    <time_frame>&lt;=72 hours</time_frame>
    <description>All stroke (hemorrhagic, ischemic, or undetermined status; disabling or nondisabling) through 72 hours post TAVR procedure or discharge</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>TAVR with Sentinel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to this group will undergo TAVR with the Sentinel® Cerebral Protection System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAVR without Sentinel</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients assigned to this group will undergo TAVR without the Sentinel® Cerebral Protection System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sentinel® Cerebral Protection System</intervention_name>
    <description>cerebral embolic protection system</description>
    <arm_group_label>TAVR with Sentinel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has documented aortic valve stenosis and is treated with an approved TAVR
             device via transfemoral access

          -  Subject has the recommended artery diameter at the site of filter placement per the
             Sentinel® Cerebral Protection System Instructions For Use: 9-15 mm for the
             brachiocephalic artery and 6.5-10 mm in the left common carotid artery.

          -  Subject (or legal representative) provides written informed consent.

        Exclusion Criteria:

          -  Subject has arterial stenosis &gt;70% in either the left common carotid artery or the
             brachiocephalic artery.

          -  Subject's brachiocephalic or left carotid artery reveals significant stenosis,
             ectasia, dissection, or aneurysm at the aortic ostium or within 3 cm of the aortic
             ostium.

          -  Subject has compromised blood flow to the right upper extremity.

          -  Subject has access vessels with excessive tortuosity.

          -  Subject has uncorrected bleeding disorders.

          -  Subject is contraindicated for anticoagulant and antiplatelet therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir Kapadia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peyton Willert</last_name>
    <phone>707-528-9300</phone>
    <email>peyton.willert@bsci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tucson Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Waggoner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medstar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Lowell Satler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sparrow Hospital</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Gaurav Dhar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Creighton - Bergan Cardiology</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Himanshu Agarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Samuel Horr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The data and study protocol for this clinical trial may be made available to other researchers in accordance with the Boston Scientific Data Sharing Policy (http://www.bostonscientific.com/en-US/data-sharing-requests.html)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

